Key result
Higher baseline B-cell and CXCR4+ bone marrow cells linked to combined functional improvement at 6 months.
Why the study?
The study aimed to identify bone marrow-derived mononuclear cell subpopulations associated with improved functional outcomes in chronic ischemic cardiomyopathy patients after cell therapy.
Are specific baseline bone marrow-derived mononuclear cell subpopulations associated with combined improvement in LVEF, LVESV, and VO2 max in patients with chronic ischemic cardiomyopathy?
Cohort (n=78)
Yes
Are specific baseline bone marrow-derived mononuclear cell subpopulations associated with combined improvement in LVEF, LVESV, and VO2 max in patients with chronic ischemic cardiomyopathy?
Specific baseline bone marrow-derived cell subsets, including B-cells and CXCR4+ BM-MNCs, are associated with improved functional and structural outcomes in patients with chronic ischemic cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Baseline B-cell and CXCR4+ frequencies may identify cell-therapy responders; leaves open whether enrichment improves outcomes in ischemic cardiomyopathy.
Taylor et al. (2016) conducted a cohort in chronic ischemic cardiomyopathy (n=78). Baseline BM-MNC immunophenotypes and progenitor cell activity vs. Patients with no change or worsened functional endpoints was evaluated on Combined improvement in left ventricular ejection fraction (LVEF), left ventricular end-systolic volume (LVESV), and maximal oxygen consumption (VO2 max). Higher baseline frequencies of B-cell and CXCR4+ bone marrow cell subpopulations were associated with combined functional improvement at 6 months (n=17) compared to no change or worsening (n=61).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: